-
Mestranol, Microglial Lysosomal Stress, and Reversibility
2026-09-09
A 2026 Aquatic Toxicology study establishes zebrafish larvae as a live model for an acquired, reversible lysosomal storage–like state in microglia after mestranol exposure. The work separates preserved phagocytic uptake from impaired intracellular digestion and links the phenotype to coordinated suppression of lysosomal and immune transcriptional programs.
-
Sulforaphane, Oxidative Stress, and NLRP3 in Colitis
2026-09-08
A 2024 mouse study shows that Sulforaphane can reduce dextran sodium sulfate-induced colitis while suppressing oxidative stress and NLRP3 inflammasome activation. Its value lies in connecting reactive oxygen species with inflammasome-associated cytokine release across animal and macrophage experiments, while leaving direct molecular targeting and clinical translation unresolved.
-
PDGF-BB Workflow for Vascular Remodeling Assays
2026-09-08
Build more reproducible vascular remodeling experiments with murine recombinant PDGF-BB, from dose-response proliferation assays to hypoxia-linked pulmonary hypertension models. This workflow connects receptor-aware stimulation with the ALDOB lactylation–mitochondrial fission findings reported in a recent reference study.
-
O-propargyl-puromycin (OPP) for Protein Synthesis
2026-09-07
O-propargyl-puromycin (OPP) converts a short translation pulse into a measurable signal for single-cell, imaging, and proteomics workflows. Applied to the Pcbp1–mitochondrial integrity problem in B cells, it can distinguish impaired protein production from changes in cell abundance or antibody secretion.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-09-07
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous research reagent for examining autophagy pathway modulation and TLR7/9-associated immune responses in autoimmune disease research. It is suitable for locally validated cellular and animal workflows, but not for DMSO- or ethanol-based stocks or long-term storage of prepared solutions.
-
Y-27632: From Cytoskeletal Control to Translation
2026-09-05
Y-27632 offers translational researchers a reversible, selective way to interrogate ROCK-dependent cytoskeletal state while separating mechanical effects from MEK/ERK–c-Myc:MAX regulation of TERT in human pluripotent stem cells. This article presents a practical framework for experimental validation, model selection, and responsible interpretation across stem cell and cancer biology research.
-
AO/PI Staining Solution: 5 Lab Scenarios
2026-09-04
This scenario-driven guide explains how AO/PI Staining Solution (SKU K2269) supports accurate live dead cell discrimination, fluorescence-based cell counting, and cytotoxicity workflows. It connects membrane-integrity measurements with practical assay design, storage, interpretation, and vendor-selection decisions.
-
Bay 11-7821: NF-κB Assay Design in Tumor Immunology
2026-09-04
Bay 11-7821 (BAY 11-7082) offers a mechanistic way to test how IKK–NF-κB signaling shapes macrophage–T-cell interactions in cancer research. This article translates recent radiotherapy and checkpoint-blockade findings into rigorous assay decisions without overstating what a chemical inhibitor can prove.
-
Ruxolitinib Workflows for JAK-STAT Research
2026-09-03
Ruxolitinib (INCB018424) combines nanomolar JAK1/JAK2 activity with practical utility in progenitor, myelofibrosis, and immune-oncology assays. This guide translates pathway inhibition into reproducible dosing, phospho-signaling, colony, and high-dimensional spectral-flow workflows while separating established evidence from cross-domain experimental opportunities.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-09-03
Hao and colleagues developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal-organic framework nanoparticle that combines photothermal ablation with localized PD-1/PD-L1 blockade. The study shows how 808 nm irradiation, redox-triggered peptide release, and immune activation can be integrated into one melanoma-oriented nanoplatform, while also highlighting the validation needed before substituting related dyes such as IR-820.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-09-02
4-Hydroxytamoxifen is a DMSO-compatible estrogen receptor modulator for controlled cell, cancer, cardiac myocyte, and selected mouse-model workflows. It should not be selected for protocols requiring water or ethanol as the primary solvent, and long-term storage of prepared solutions should be avoided.
-
CDK9 inhibitor A3294: Practical Workflow Guide
2026-09-02
CDK9 inhibitor A3294 provides a selective serine/threonine kinase inhibitor for examining CDK9-dependent transcription elongation, P-TEFb activity, and exploratory HIV-1 propagation assays. The available evidence is limited to the product dossier, so it should be validated in the intended assay and should not be treated as a pan-CDK reagent, universal cytotoxicity control, or therapeutic predictor.
-
Leupeptin: Precision Protease Control in Translation
2026-09-01
Leupeptin hemisulfate salt is more than a conventional protease-blocking reagent. Its reversible, competitive mechanism provides a controllable way to interrogate protein degradation, autophagy, and selected viral replication workflows, while a modern TET2 metabolite-binding protocol offers a useful model for orthogonal validation and translational assay design.
-
RepSox: ALK5 Inhibition in iPSC Workflows
2026-09-01
RepSox is a potent and selective ALK5 inhibitor for studying TGF-β signaling, induced pluripotent stem cell reprogramming, and cell differentiation. Its reported 4 nM ALK5 inhibition supports pathway-focused experiments, but current hiPSC-derived platelet benchmarks do not establish RepSox as a validated platelet-differentiation reagent.
-
Liproxstatin-1 in Ferroptosis Assay Design
2026-08-31
Liproxstatin-1 is a potent ferroptosis inhibitor for testing whether lipid peroxidation drives cell injury. This guide connects its validated rescue profile with a sex-specific salivary gland study and offers a causal, tissue-aware assay strategy.